Double Bond Pharmaceutical International AB (publ)

NGM:DBP B Stock Report

Market Cap: SEK 42.2m

Double Bond Pharmaceutical International Past Earnings Performance

Past criteria checks 0/6

Double Bond Pharmaceutical International's earnings have been declining at an average annual rate of -6.9%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been declining at an average rate of 26.7% per year.

Key information

-6.9%

Earnings growth rate

19.7%

EPS growth rate

Pharmaceuticals Industry Growth30.5%
Revenue growth rate-26.7%
Return on equity-543.6%
Net Margin-1,363.7%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Double Bond Pharmaceutical International makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NGM:DBP B Revenue, expenses and earnings (SEK Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 241-1580
30 Jun 241-1780
31 Mar 241-16100
31 Dec 231-17100
30 Sep 231-16100
30 Jun 231-17100
31 Mar 231-1580
31 Dec 221-1580
30 Sep 221-370
30 Jun 221-570
31 Mar 221-880
31 Dec 211-990
30 Sep 211-2180
30 Jun 210-2280
31 Mar 211-1980
31 Dec 201-1880
30 Sep 204-1380
30 Jun 204-1180
31 Mar 205-1080
31 Dec 194-880
30 Sep 192-990
30 Jun 191-980
31 Mar 191-1080
31 Dec 181-1180
30 Sep 180-1280
30 Jun 180-1380
31 Mar 181-1390
31 Dec 171-1390
30 Sep 171-1280
30 Jun 171-1180
31 Mar 170-1070
31 Dec 160-860
30 Sep 160-860
30 Jun 160-760
31 Mar 160-550
31 Dec 150-440

Quality Earnings: DBP B is currently unprofitable.

Growing Profit Margin: DBP B is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: DBP B is unprofitable, and losses have increased over the past 5 years at a rate of 6.9% per year.

Accelerating Growth: Unable to compare DBP B's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: DBP B is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (9.5%).


Return on Equity

High ROE: DBP B has a negative Return on Equity (-543.6%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 02:38
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Double Bond Pharmaceutical International AB (publ) is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution